to - 医索

找到约 1557 条结果

Nivolumab plus ipilimumab vs lenvatinib or sorafenib asfirst-line treatment for unresectable hepatocellularcarcinoma first results from CheckMate 9DW

医客学院 - 会议报告集

New Tricks With Old Tools Acrossthe Spectrum of Pancreatic cancer

医客学院 - 会议报告集

International, open-label phase 2 study of regorafenibplus pembrolizumab in patients with advancedhepatocellular carcinoma previously treated withimmune checkpoint inhibitors

医客学院 - 会议报告集

Development and validation of Al-assisted transcriptomicsignatures to personalize adjuvant chemotherapy in patientswith resectable pancreatic ductal adenocarcinoma

医客学院 - 会议报告集

Addition of stereotactic body radiotherapyto systemic chemotherapy in locallyadvanced cholangiocarcinoma(ABC-07)

医客学院 - 会议报告集

SACI-0 HR A randomized phase ll trial ofsacituzumab govitecan with or without pembrolizumabin patients with metastatic hormone receptor-positive!HER2-negative breast cancer

医客学院 - 会议报告集

H3B-6545 in women with locally advancedmetastaticestrogen receptor-positive,HER2-negative breast cancer

医客学院 - 会议报告集

First-line inavolisibplacebo palbociclib fulvestrant(InavoPbo Palbo Fulv) in patients (pts) with PiK3cA-mutated.hormone receptor-positive, HER2-negative locally advancedmetastaticbreast cancer

医客学院 - 会议报告集

Development and validation of RsclinN toolfor hormone receptor-positive(HR ),HER2-negative(HER2-)node-positive breast cancer

医客学院 - 会议报告集

Datopotamab deruxtecan (Dato-DXd)vs chemotherapy inpreviously-treated inoperable or metastatic hormonereceptor-positive, HER2-negative (HR HER2-) breast cancerPatient-reported outcomes(PROs) from

医客学院 - 会议报告集

今日实时热搜